Eli Lilly stock (LLY) slips as Ventyx deal, Zepbound arthritis data and TuneLab AI tie-up come into view
Eli Lilly shares slipped 0.4% to $1,081 Friday after announcing a $1.2 billion cash deal to buy Ventyx Biosciences. A Phase 3 trial showed Zepbound plus Taltz improved psoriatic arthritis outcomes in overweight adults. Schrodinger will launch Lilly’s TuneLab AI platform on LiveDesign in Q1.